o-Toluidine is produced industrially by nitration of toluene to give a mixture of nitrotoluenes, favoring the ortho isomer. This mixture is separated by distillation. 2-Nitrotoluene is hydrogenated to give o-toluidine.[2]
The conversion of o-toluidine to the diazonium salt gives access to the 2-bromo, 2-cyano-, and 2-chlorotoluene derivatives.[3][4][5] N-acetylation is also demonstrated.[6]
o-Nitrosotoluene is suspected of causing bladder cancer in rats.[10][11][12] Nitrosotoluene exposure has been researched in a number of different degrees in animals.[13][14][15][16]
Carcinogenicity
In the U.S., o-toluidine was first listed in the Third Annual Report on Carcinogens as 'reasonably anticipated to be a human carcinogen' in 1983, based on sufficient evidence from studies in experimental animals. The Report on Carcinogens (RoC) is a U.S. congressionally-mandated, science-based public health report that identifies agents, substances, mixtures, or exposures in the environment that pose a hazard to people residing in the United States[17] Since then, other cancer related studies have been published and the listing of o-toluidine was changed to 'known to be a human carcinogen'. o-toluidine was especially linked to bladder cancer. This was done 31 years later in the Thirteenth Report on Carcinogens (2014).[14] The International Agency for Research on Cancer (IARC) has classified o-toluidine as 'carcinogenic to humans (group 1)'.[18]
The metabolism of o-toluidine involves many competing activating and deactivating pathways, including N-acetylation, N-oxidation, and N-hydroxylation, and ring oxidation.[22] 4-Hydroxylation and N-acetylation of toluidine are the major metabolic pathways in rats. The primary metabolism of o-toluidine takes place in the endoplasmic reticulum. Exposure to o-toluidine enhances the microsomal activity of aryl hydrocarbon hydroxylase (particularly in the kidney), NADPH-cytochrome c reductase and the content of cytochrome P-450. Cytochrome P450–mediated N-hydroxylation to N-hydroxy-o-toluidine, a carcinogenic metabolite, occurs in the liver. N-Hydroxy-o-toluidine can be either metabolized to o-nitrosotoluene or conjugated with glucuronic acid or sulfate and transported to the urinary bladder via the blood. Once in the bladder, N-hydroxy-o-toluidine can be released from the conjugates in an acidic urine environment to either react directly with DNA or be bio-activated via sulfation or acetylation by cytosolic sulfotransferases or N-acetyltransferases (presumably NAT1).[14] The postulated activated form (based on comparison with other aromatic amines), N-acetoxy-o-toluidine, is a reactive ester that forms electrophilic arylnitrenium ions that can bind to DNA.[22][23][10] Other activation pathways (ring-oxidation pathways) for aromatic amines include peroxidase-catalyzed reactions that form reactive metabolites (quinone-imines formed from nonconjugated phenolic metabolites) in the bladder. These metabolites can produce reactive oxygen species, resulting in oxidative cellular damage and compensatory cell proliferation. Support for this mechanism comes from studies of oxidative DNA damage induced by o-toluidine metabolites in cultured human cells (HL-60), calf thymus DNA, and DNA fragments from key genes thought to be involved in carcinogenesis (the c-Ha-ras oncogene and the p53 tumor-suppressor gene).[24][25] Also supporting this mechanism are observations of o-toluidine-induced DNA damage (strand breaks) in cultured human bladder cells and bladder cells from rats and mice exposed in vivo to o-toluidine.[26][27]
Excretion
The main excretion pathway is through the urine where up to one-third of the administered compound was recovered unchanged. Major metabolites are 4-amino-m-cresol and to a lesser extent, N-acetyl-4-amino-m-cresol,[20] azoxytoluene, o-nitrosotoluene, N-acetyl-o-toluidine, N-acetyl-o-aminobenzyl alcohol, anthranilic acid, N-acetyl-anthranilic acid, 2-amino-m-cresol, p-hydroxy-o-toluidine. Conjugates that were formed were predominated by sulfate conjugates over glucuronide conjugates by a ratio of 6:1.
^Nomenclature of Organic Chemistry: IUPAC Recommendations and Preferred Names 2013 (Blue Book). Cambridge: The Royal Society of Chemistry. 2014. p. 669. doi:10.1039/9781849733069-FP001. ISBN978-0-85404-182-4. The names 'toluidine', 'anisidine', and 'phenetidine' for which o-, m-, and p- have been used to distinguish isomers, and 'xylidine' for which numerical locants, such as 2,3-, have been used, are no longer recommended, nor are the corresponding prefixes 'toluidine', 'anisidino', 'phenetidine', and 'xylidino'.
^Hazardous Substances Data Bank (HSDB, online database). National Toxicology Information Program. National Library of Medicine, Bethesda, MD: U.S. Department of Health and Human Services. 1997.
^Clayton, G. D.; Clayton, F. E., eds. (1981). Patty's Industrial Hygiene and Toxicology. Vol. 2A (3rd rev. ed.). New York: John Wiley & Sons.
^Birnier, G.; Neumann, H. (1988). "Biomonitoring of aromatic amines. II: Haemoglobin binding of some monocyclic aromatic amines". Arch. Toxicol. 62 (2–3): 110–115. doi:10.1007/BF00570128. PMID3196145. S2CID33391149.
^Eyer, P. (1983). "The Red Cell as a Sensitive Target for Activated Toxic Arylamines". Toxicology in the Use, Misuse, and Abuse of Food, Drugs, and Chemicals. Archives of Toxicology, Supplement. Vol. 6. pp. 3–12. doi:10.1007/978-3-642-69083-9_1. ISBN978-3-540-12392-7. PMID6578736.
^Hecht, S. S.; El-Bayoumy, K.; Rivenson, A.; Fiala, E. (1983). "Bioassay for carcinogenicity of 1,2-dimethyl-4-nitrosobiphenyl, o-nitrosotoluene, nitrosobenzene and the corresponding amines in Syrian golden hamsters". Cancer Lett. 20 (3): 349–354. doi:10.1016/0304-3835(83)90034-4. PMID6627231.
^ abHiles, R. C.; Abdo, K. M. (1990). "5. ortho-Toluidine". In Buhler, D. R.; Reed, D. J. (eds.). Nitrogen and Phosphorus Solvents (2nd ed.). Elsevier. pp. 202–207.
^ abc"o-Toluidine"(PDF). Report on Carcinogens (13th ed.). US National Institute of Health.
^Gregg, N.; et al. (1998). o-Toluidine. World Health Organization. pp. 5–22. ISBN92-4-153007-3. (NLM classification: QV 235.)
^Rubino, G. F.; Scansetti, G.; Piolatto, G.; Fira, E. (1982). "The carcinogenic effect of aromatic amines: An epidemiological study on the role of o-toluidine and 4,4′-methylenebis(2-methylaniline) in inducing bladder cancer in man". Env. Res. 27 (2): 241–254. Bibcode:1982ER.....27..241R. doi:10.1016/0013-9351(82)90079-2. PMID7084156.
^Burwell, S. M. (2014). Report on Carcinogens (13th ed.).
^Cheever, K.; Richards, D.; Plotnick, H. (1980). "Metabolism of o-, m- and p-toluidine in the adult male rat". Toxicol. Appl. Pharmacol. 56 (3): 361–369. doi:10.1016/0041-008x(80)90069-1. PMID7222020.
^ abSon, O. S.; Everett, D. W.; Fiala, E. S. (1980). "Metabolism of o-[methyl-14C]toluidine in the F344 rat". Xenobiotica. 10 (7–8): 457–468. doi:10.3109/00498258009033781. PMID7445517.
^Brock, W. J.; Hundley, S. G.; Lieder, P. H. (1990). "Hepatic macromolecular binding and tissue distribution of ortho- and para-toluidine in rats". Toxicol. Lett. 54 (2–3): 317–325. doi:10.1016/0378-4274(90)90199-v. PMID1701932.
^Ohkuma, Y. Y.; Hiraku, S.; Oikawa, S.; Yamashita, N.; Murata, M.; Kawanishi, S. (1999). "Distinct mechanisms of oxidative DNA damage by two metabolites of carcinogenic o-toluidine". Arch. Biochem. Biophys. 372 (1): 97–106. doi:10.1006/abbi.1999.1461. PMID10562421.
^Robbiano, L.; Carrozzino, R.; Bacigalupo, M.; Corbu, C.; Brambilla, G. (2002). "Correlation between induction of DNA fragmentation in urinary bladder cells from rats and humans and tissue-specific carcinogenic activity". Toxicology. 179 (1–2): 115–128. doi:10.1016/s0300-483x(02)00354-2. PMID12204548.
^Sekihashi, K.; Yamamoto, A.; Matsumura, Y.; Ueno, S.; Watanabe-Akanuma, M.; Kassie, F; Knasmuller, S.; Tsuda, S.; Sasaki, Y. F. (2002). "Comparative investigation of multiple organs of mice and rats in the comet assay". Mutat. Res. 517 (1–2): 53–75. doi:10.1016/s1383-5718(02)00034-7. PMID12034309.
^Ryota Higuchi; Tatsuki Fukami; Miki Nakajima; Tsuyoshi Yokoi (2013). "Prilocaine- and Lidocaine-Induced Methemoglobinemia Is Caused by Human Carboxylesterase-, CYP2E1-, and CYP3A4-Mediated Metabolic Activation". Drug Metab. Dispos. 41 (6): 1220–1230. doi:10.1124/dmd.113.051714. PMID23530020. S2CID9741909.